NPPA overcharging data raises medicine affordability concerns
Quick dive
- The Supreme Court questioned why trade-margin restrictions could not extend beyond non-scheduled anti-cancer medicines.
- The report states that NPPA demands since 2009 total about ₹5,265 crore, of which roughly ₹4,460 crore remains outstanding.
- In 2025–26, NPPA recorded 133 overcharging cases, after 148 cases in 2022–23.
- The issue concerns differences between supply prices and patient charges and the limits of enforcement and recovery.
- exam_relevance: tests the distinction between scheduled and non-scheduled medicines, trade margins, NPPA enforcement and access to essential healthcare through concrete recovery figures.
Full explanation
This explanation is available with full current-affairs access.
Log in to continue